Concert pharmaceuticals presents positive 48-Week results from Phase 2 Clinical Trial of CTP-499 in diabetic kidney disease

28-04-2014 Business Wire HealthComments (0)

Concert PharmaceuticalsPharmaceuticalUSA

Concert Pharmaceuticals announced 48-week results of its Phase 2 clinical trial of CTP-499 in patients with diabetic kidney disease

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top